

FDI – IVT
FDI – T
DS-cavl
delFP
kDa
140
110
80
60
50
40
30
20

FIG. 1B



NC
DS-cavl
FD
1
2
3
kDa
110
80
60
50
40
30

FIG. 1A



HEK Transfection
HSkMC Nucleofection
160
120
80
60
50
40
30
20
15
10
DS-Cav1
Mblanker
FD1 (40.6)
FD1 (40.7)
FD2 Sup (42.2)
FD2 Sup (42.3)
FD3 (45.2)
FD3 (45.3)
Cell Control

FIG. 2A

FIG. 2B




FIG. 3



RSV F ELISA Titer
Log2 Titer-1
24
22
20
18
16
14
12
10
8
6
19.48
19.08
17.49
17.49
D0
D28
D56
D0
D28
D56
FD1
FD2
FD3
Protein
Lipid A LNP
Formulation
Pre-F NP
+AF03

FIG. 4A



RSV Microneutralization Titer
Log2 Titer-1
16
14
12
10
8
6
4
2
11.79
10.42
10.07
6.78
D0
D28
D56
D0
D28
D56
FD1
FD2
FD3
Protein
Lipid A LNP
Formulation
Pre-F NP
+AF03

FIG. 4B



Competitive ELISA
Log2 IT50
0
2
4
6
8
D25
Synagis
131-2a
D25
Synagis
131-2a
D25
Synagis
131-2a
FD2
FD3
PreF-NP + Alum

FIG. 5



RSV Microneutralization Titer
Log2 Titer-1
18
16
14
12
10
8
6
4
2
12.33
12.50
12.49
12.54
7.38
8.05
D0
D14
D28
D0
D14
D28
FD2
FD3
Lipid A LNP
Formulation

FIG. 6B



RSV-F Antibody Titer
Log2 Titer-1
22
20
18
16
14
12
10
8
17.49
17.01
17.23
17.38
13.69
13.37
Day 0
Day 14
Day 28
Day 0
Day 14
Day 28
FD2
FD3
Lipid A LNP
Formulation

FIG. 6A



RSV F ELISA in NHP
Log2 Titer-1
20
18
16
14
12
10
8
15.58
15.56
14.67
13.27
14.71
11.30
17.59
D0
D21
D35
Lipid A LNP – FD3 mRNA
Lipid B LNP – FD3 mRNA
Lipid C LNP – FD3 mRNA
Lipid E LNP – FD3 mRNA
Lipid D LNP – FD3 mRNA
MC3 LNP – FD3 mRNA
Pre-F NP + Al(OH)3

FIG. 7



RSV neutralization in NHP
Log2 Titer-1
14
12
10
8
6
4
9.86
10.03
8.51
6.93
8.84
5.31
10.97
D0
D21
D35
Lipid A LNP – FD3 mRNA
Lipid B LNP – FD3 mRNA
Lipid C LNP – FD3 mRNA
Lipid E LNP – FD3 mRNA
Lipid D LNP – FD3 mRNA
MC3 LNP – FD3 mRNA
Pre-F NP + Al(OH)3

FIG. 8




FIG. 9A




FIG. 9B

- RSV-F WT (membrane)
- RSV-F foldon (secreted)
- RSV-F RF8140 (membrane)
- RSV Pre-F NP + Alum-85




FIG. 10B




FIG. 10A



Neut titer relative to mock (fold rise):
10.0x
19.6x
23.9x
19.5x
<0.0001
0.0301
<0.0001
<0.0001
<0.0001
Anti-RSV Neutralization titer (Log2)
14
12
10
8
6
4
2
0
2.2
6.5
1.9
5.4
6.4
6.0
Immunogen: (0.37 ug/ml)
None
Pre-F-NP
None
FD-1
FD-2
FD-3
Lipid F LNP Formulation

FIG. 11